Adult immunization vaccine , dose, duration
Reading File
Searching the Web
adult immunization schedule 2025 2026 CDC ACIP vaccines dose
Finding Sources
Reading Web Page
https://www.cdc.gov/mmwr/volumes/74/wr/mm7402a3.htm
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive data from both the textbooks and the latest CDC/ACIP 2025 schedule. Here is a complete, organized reference:
Adult Immunization Schedule - Vaccine, Dose & Duration
Based on ACIP/CDC 2025 Recommended Adult Immunization Schedule (updated April 2026) and Goldman-Cecil Medicine / Textbook of Family Medicine.
Routine Vaccines for ALL Adults
| Vaccine | Dose | Schedule / Interval | Age Group |
|---|---|---|---|
| Influenza (IIV3 / RIV3) | 1 dose | Annually (every year) | 19+ years |
| Influenza (HD-IIV3, RIV3, aIIV3) | 1 dose | Annually - preferred for ≥65 | ≥65 years |
| Tdap / Td (Tetanus, Diphtheria, Pertussis) | 1 dose Tdap once, then Td booster | Tdap x1 (if not received), then Td every 10 years | All adults |
| COVID-19 | 1-2+ doses of updated vaccine | Annually (updated seasonal formulation); see notes | All adults |
Vaccines Based on Age
| Vaccine | Dose / Schedule | Age |
|---|---|---|
| HPV (Human Papillomavirus) | 2 doses if started at age 9-14 (0, 6-12 months); 3 doses (0, 1-2, 6 months) if started ≥15 yrs or immunocompromised | Up to 26 years routinely; shared decision-making 27-45 years |
| Zoster Recombinant (RZV / Shingrix) | 2 doses, 2-6 months apart | Routinely at ≥50 years; immunocompromised adults ≥19 years |
| Pneumococcal (PCV20 or PCV21) | 1 dose PCV20 or PCV21 alone OR PCV15 followed by PPSV23 ≥1 year later | ≥65 years (or younger with risk factors) |
| RSV Vaccine (Abrysvo / Arexvy / mResvia) | 1 dose (single dose only) | ≥60 years routinely; 50-59 years if at increased risk (updated June 2025) |
| MMR (Measles, Mumps, Rubella) | 1-2 doses | Adults born 1957 or later lacking evidence of immunity |
Catch-up / Risk-Based Vaccines
| Vaccine | Dose | Schedule | Indication |
|---|---|---|---|
| Hepatitis A (HepA) | 2 doses | 0 and 6-12 months (Havrix/Vaqta) OR 3-dose Twinrix at 0, 1, 6 months | Travel, liver disease, MSM, drug use |
| Hepatitis B (HepB) | 2 or 3 doses | Heplisav-B: 2 doses at 0, 1 month; Engerix/Recombivax: 3 doses at 0, 1, 6 months | All unvaccinated adults; diabetes (19-59 yrs) |
| Varicella (VAR) | 2 doses, 4-8 weeks apart | 0 and 4-8 weeks | Adults without evidence of immunity (born ≥1980) |
| Meningococcal MenACWY | 1 dose; booster every 5 years if ongoing risk | Single dose or series | Asplenia, complement deficiency, travel, college freshmen |
| Meningococcal B (MenB) | 2 doses (Bexsero: 0, 6 months; Trumenba: 0, 1-2, 6 months for high-risk) | Healthy 16-23 yrs: 2 doses per shared decision-making; high-risk: 3-dose series (0, 1-2, 6 months) | Asplenia, complement deficiency, outbreaks |
| Pneumococcal PPSV23 | 1 dose | At 65 (if PCV15 used first, ≥1 year later) or for high-risk younger adults | COPD, diabetes, asplenia, smokers, CKD |
| Mpox (JYNNEOS) | 2 doses SC, 4 weeks apart | 0 and 28 days | MSM, sex workers, lab workers |
| Meningococcal MenABCWY (Penmenvy) | Per schedule | Combined vaccine when both MenACWY + MenB indicated at same visit | ≥10 years at increased risk |
Special Population Notes
- Pregnancy: Tdap in every pregnancy (ideally 27-36 weeks); Influenza any trimester; RSV vaccine 32-36 weeks gestation (Abrysvo). Live vaccines (MMR, varicella, LAIV) are contraindicated.
- Immunocompromised (HIV with CD4 <200, high-dose steroids, chemotherapy): Avoid live vaccines (MMR, VAR, LAIV, Zoster live); use inactivated alternatives. RZV (Shingrix) is safe.
- Asplenia: PCV + PPSV23, MenACWY, MenB, Hib - all indicated.
- Healthcare workers: MMR x2 doses, Varicella x2 doses, Hepatitis B with serology check, annual influenza.
- Chronic liver disease: HepA, HepB.
Quick Reference Summary Table
| Vaccine | # of Doses | Key Interval |
|---|---|---|
| Influenza | 1 | Every year |
| COVID-19 | 1+ updated annually | Per season |
| Tdap | 1 Tdap then Td booster | Td every 10 years |
| HPV | 2 or 3 | 0, 6-12 months (2-dose); 0, 1-2, 6 months (3-dose) |
| Shingrix (RZV) | 2 | 2-6 months apart |
| Pneumococcal PCV20/PCV21 | 1 | Single dose (≥65 yrs) |
| RSV | 1 | Single lifetime dose |
| HepA | 2 | 6-12 months apart |
| HepB (Heplisav-B) | 2 | 1 month apart |
| HepB (Engerix/Recombivax) | 3 | 0, 1, 6 months |
| Varicella | 2 | 4-8 weeks apart |
| MMR | 1-2 | ≥28 days apart if 2 doses |
| MenACWY | 1 (+booster q5yr if ongoing risk) | Every 5 years if high risk |
| MenB (Bexsero) | 2 (healthy) / 3 (high risk) | 0, 6 months / 0, 1-2, 6 months |
| Mpox (JYNNEOS) | 2 | 28 days apart |
Sources:
- ACIP/CDC 2025 Adult Immunization Schedule (updated April 2026)
- Goldman-Cecil Medicine (9780323930345), Table E-15-3
- Textbook of Family Medicine 9e (9780323239905), p. 131
Note: The 2025 schedule updates include: trivalent influenza vaccines (replacing quadrivalent), PCV21 added as a new option, RSV now recommended for 50-59 year olds at increased risk (June 2025 update), and revised MenB scheduling with Bexsero.
Pneumococcal vaccine schedule
Finding Sources
Searching the Web
pneumococcal vaccine schedule adults 2025 2026 PCV21 PCV20 PCV15 PPSV23 ACIP CDC
Finding Sources
Reading Web Page
https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations…
Finding Sources
Reading Web Page
https://dig.pharmacy.uic.edu/faqs/2025-2/june-2025-faqs/what…
Reading File
I now have everything needed for a comprehensive, current answer. Here it is:
Pneumococcal Vaccine Schedule (2025-2026 ACIP/CDC)
Available Vaccines at a Glance
| Vaccine | Brand Name | Serotypes Covered |
|---|---|---|
| PCV15 | Vaxneuvance | 15 serotypes |
| PCV20 | Prevnar 20 | 20 serotypes (includes serotype 4) |
| PCV21 | Capvaxive | 21 serotypes (broadest coverage; does NOT include serotype 4) |
| PPSV23 | Pneumovax 23 | 23 serotypes (polysaccharide, T-cell independent) |
Key 2025 update: Routine age-based recommendation expanded from ≥65 years to ≥50 years (effective October 2024). PCV21 added as a new option.
Adults ≥50 Years - Routine Schedule
If NEVER vaccinated (PCV-naive):
| Option | Vaccine | Interval |
|---|---|---|
| Option A (preferred) | PCV20 or PCV21 - 1 dose only | Series complete. No PPSV23 needed. |
| Option B | PCV15 - 1 dose, THEN PPSV23 - 1 dose | At least 1 year later (minimum 8 weeks if immunocompromised, cochlear implant, or CSF leak) |
If previously received PCV15 only:
- Give PPSV23 ≥1 year later (series then complete)
If previously received PPSV23 only:
- Give PCV20 or PCV21 ≥1 year after PPSV23
If previously received PCV13 only:
- Give PCV20 or PCV21 ≥1 year later (PPSV23 no longer recommended to complete a PCV13 series)
If previously received PCV13 + PPSV23:
- Adults 65+: Shared clinical decision-making - may receive PCV20 or PCV21 (optional, for additional serotype coverage)
- No routine additional vaccination required
If previously received PCV15 + PPSV23 or PCV20 or PCV21:
- Series complete. No further pneumococcal vaccines recommended.
Adults 19-49 Years - Risk-Based Only
Pneumococcal vaccination for this age group is NOT routine - it is indicated only for specific high-risk conditions:
| Risk Condition | Recommended Schedule |
|---|---|
| Immunocompromising conditions (HIV, leukemia, lymphoma, renal failure, nephrotic syndrome, immunosuppressive therapy, solid organ transplant, asplenia, sickle cell) | PCV20 or PCV21 x1 dose; OR PCV15 then PPSV23 ≥8 weeks later |
| Cochlear implant or CSF leak | Same as above (≥8 week interval acceptable) |
| Chronic heart disease, lung disease, liver disease, diabetes, alcoholism, smokers | Same series as above |
Serotype 4 Consideration
In communities where serotype 4 causes ≥30% of pneumococcal disease, choose:
- PCV20 alone, OR
- PCV15 + PPSV23
Because PCV21 does NOT cover serotype 4, it may offer suboptimal protection in those settings.
Summary Flow Diagram (Adults ≥50, Vaccine-naive)
No prior pneumococcal vaccine?
|
├── PCV20 or PCV21 → DONE (1 dose, series complete)
|
└── PCV15 → wait ≥1 year (or ≥8 weeks if immunocompromised) → PPSV23 → DONE
Special Populations
| Population | Key Point |
|---|---|
| Immunocompromised (DMARD users, HIV, transplant) | Minimum interval between PCV15 and PPSV23 reduced to 8 weeks; note that rituximab and methotrexate reduce vaccine immunogenicity |
| Asplenia / sickle cell | High priority; treat as immunocompromised |
| Chronic kidney disease / hemodialysis | High risk; follow risk-based schedule starting at age 19 |
| Rheumatologic disease on DMARDs | PCV20 preferred (single dose, maximal benefit); if PCV13 already received, add PCV20 for improved immunogenicity |
| Healthcare workers | No additional pneumococcal requirements beyond age/risk-based schedule |
| Pregnancy | Defer non-urgent pneumococcal vaccination until after delivery if possible |
How Many Doses Total?
| Scenario | Total Doses |
|---|---|
| PCV20 or PCV21 alone | 1 dose (series complete) |
| PCV15 + PPSV23 | 2 doses total |
| PPSV23 first, then PCV20/21 | 2 doses total |
| PCV13 + later PCV20/21 (catch-up) | 2 doses total |
No booster doses are currently recommended for any pneumococcal vaccine in adults (unlike meningococcal).
Sources:
- CDC Pneumococcal Vaccine Recommendations (updated 2025)
- CDC Vaccine Timing Job Aid for Adults (March 2025)
- ACIP MMWR 2025 Adult Immunization Schedule
- Firestein & Kelley's Textbook of Rheumatology - Pneumococcal Vaccination section
- Goldman-Cecil Medicine, Table E-15-3
This is a shared conversation. Sign in to Orris to start your own chat.